Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV and Observational Study to Evaluate Safety and Effectiveness of Temozolomide (Amitzo, NanoAlvand) Therapy in in Patients With Grade III and IV Glioma Tumors

NCT07675070 is registered in ClinicalTrials.gov with NanoAlvand as lead sponsor.

NCT NCT07675070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07675070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV and Observational Study to Evaluate Safety and Effectiveness of Temozolomide (Amitzo, NanoAlvand) Therapy in in Patients With Grade III and IV Glioma Tumors
Lead sponsor
NanoAlvand
Phase
Observational
Overall status
Recruiting
Start date
March 22, 2026
Completion date
November 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, grade iii glioma, grade iv glioma